# Allotera Therapeutics (formerly Wugen)

Source: https://onco.cc/companies/allotera-therapeutics/  
OnCo record `allotera-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Allotera, formerly Wugen, makes off-the-shelf CAR T-cell therapies from healthy donor cells for T-cell leukaemias and lymphomas, which are hard to treat with conventional CAR T because the cancer cells look like the therapy cells. Its lead product is in a global pivotal trial.

## Summary

Allotera Therapeutics (renamed from Wugen in July 2026) is a St. Louis clinical-stage company developing allogeneic, off-the-shelf cell therapies for haematological malignancies. Lead candidate soficabtagene geleucel (sofi-cel, formerly WU-CART-007) is an anti-CD7 allogeneic CAR T-cell therapy in the global pivotal T-RRex trial for relapsed or refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma, with further work in T-cell non-Hodgkin lymphoma, acute myeloid leukaemia and autoimmune indications. The programme was selected for the FDA's CMC Development and Readiness Pilot. In July 2026 the company closed a $35 million financing of equity and venture debt, bringing its Series C to $150 million and total capital raised to $150 million on top of the $115 million Series C announced in late 2025, to fund T-RRex, manufacturing scale-up and team growth.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: St. Louis, MO
- Type: cell-therapy
- Website: https://alloteratx.com/

## Notes

- wugen.com redirects to alloteratx.com. Investor names not given in the fetched release. Earlier Wugen rounds (for example the 2021 Series B) not sourced.

## Sources

- Official website: https://alloteratx.com/
- $35 million financing and rename (July 2026): https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- trials: [A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)](https://onco.cc/trials/nct06514794/)

---
JSON: https://onco.cc/api/v1/entities/allotera-therapeutics.json